Researchers at the University of Canterbury are working on new forms of tumour detection in the hope of reducing the annual cancer toll. [ + ]

Sir Walter Murdoch Adjunct Professor Thomas Gilbert is part of an international team that has helped decode the genetic blueprint of the common pigeon (Rock Pigeon/Feral Pigeon) in a breakthrough that sheds light into the minute building blocks of evolution. [ + ]

Phosphagenics (ASX:POH) has solved the crystallisation problems with its oxycodone patch and is aiming to re-enter the clinic by the end of this quarter. [ + ]

In a letter to shareholders, Bioniche’s (ASX:BNC) CEO has laid out some plans for the future of bladder cancer treatment Urocidin following its split with former commercialisation partner Endo Pharmaceuticals. [ + ]

Cellmid (ASX:CDY) has secured an option agreement with Japan’s Fujikura covering its midkine cancer diagnostics technology in latex-based tests. [ + ]

BioDiem (ASX:BDM) and the QIMR are moving to proof-of-concept testing of BioDiem’s antimicrobial in the parasitic worms that cause the major tropical disease schistosomiasis. [ + ]

Kählig Antriebstechnik GmbH has appointed maxon motor Australia Pty Ltd as its distributor for Australia and New Zealand. [ + ]

Baxter Innovation Hub has launched its new commercialisation service, Baxter Commercialisation, comprising an experienced team of industry specialists dedicated to assisting Australian inventors and entrepreneurs in expanding their business and selling their ideas to the world. [ + ]

Mesoblast (ASX:MSB) has made gains on the ASX following an announcement it has secured further patents covering its technology in the US and China. [ + ]

Australian researchers have unravelled a longstanding mystery of obesity: why is it sometimes counterproductive for obese people to diet? [ + ]

The first national audit of its kind ever to be held in Australia recorded information about 411 different activities that aim to engage ordinary people with science. [ + ]

Tests of tissue engineered by Allied Healthcare’s (ASX:AHZ) ADAPT technology support its ability to be used for a “truly regenerative treatment”, according to its CEO. [ + ]

An animal trial has shown Cynata’s mesenchymoangioblasts (MCA) cells can help improve blood flow in mice with induced critical limb ischemia. [ + ]

A positive result from an animal trial of Calzada (ASX:CZD) subsidiary Metabolic Pharmaceuticals’ osteoarthritis treatment could lead to phase II human trials beginning soon. [ + ]

Sirtuin, which is known for its link to ageing, has been associated with pancreatic cancer, raising the prospect of new treatments. [ + ]